Cite
One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.
MLA
Bergman, Martin, et al. “One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.” Advances in Therapy, vol. 40, no. 10, Oct. 2023, pp. 4493–503. EBSCOhost, https://doi.org/10.1007/s12325-023-02619-6.
APA
Bergman, M., Chen, N., Thielen, R., & Zueger, P. (2023). One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib. Advances in Therapy, 40(10), 4493–4503. https://doi.org/10.1007/s12325-023-02619-6
Chicago
Bergman, Martin, Naijun Chen, Richard Thielen, and Patrick Zueger. 2023. “One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.” Advances in Therapy 40 (10): 4493–4503. doi:10.1007/s12325-023-02619-6.